The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man.
D000804:Angiotensin II / Q000032:analysis* / Q000097:blood / Q000652:urine; D000806:Angiotensin-Converting Enzyme Inhibitors; D001920:Bradykinin / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000378:metabolism*; D007705:Kinins / Q000032:analysis* / Q000097:blood / Q000652:urine; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000494:pharmacology*; D011188:Potassium / Q000008:administration & dosage; D011458:Prostaglandins E / Q000032:analysis* / Q000097:blood / Q000652:urine; D012083:Renin / Q000097:blood; D012964:Sodium / Q000008:administration & dosage / Q000494:pharmacology; D013722:Teprotide / Q000494:pharmacology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D007705:Kinins; D009842:Oligopeptides; D011458:Prostaglandins E; D000804:Angiotensin II; D012964:Sodium; D013722:Teprotide; D012083:Renin; D011188:Potassium; D001920:Bradykinin